BackProto Script Pharmaceutical Overview

Proto Script Pharmaceutical Receivables

Track Proto Script Pharmaceutical's receivables ($170K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$166438.00
↓ 32.71% YoYΔ $-80888.00 vs prior year quarter

Peer trimmed avg / median

Loading

Proto Script Pharmaceutical Receivables History

Loading

Proto Script Pharmaceutical vs. peers: Receivables Comparison

Loading

Proto Script Pharmaceutical Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Proto Script Pharmaceutical (PSCR) FAQ

Proto Script Pharmaceutical posts a receivables of $170K as of September 2017. That compares with $250K in the prior-year period — down 32.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Proto Script Pharmaceutical's receivables was $250K. The latest reading is $170K — a 32.7% year-over-year decrease (period ending September 2017). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Proto Script Pharmaceutical's financial statement story. At $170K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PSCR's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Proto Script Pharmaceutical's other metric pages and overview cover the third.